Tech Company Financing Transactions
Neurovance Funding Round
Neurovance, based in Cambridge, raised $1.5 million from private investors.
Transaction Overview
Company Name
Announced On
12/3/2016
Transaction Type
Debt
Amount
$1,500,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 7 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
43 Thorndike Street S1-3
Cambridge, MA 02141
USA
Cambridge, MA 02141
USA
Phone
Website
Email Address
Overview
Neurovance is a clinical stage neuroscience-focused company. Following development of centanafadine SR (formerly EB-1020 SR) for adult ADHD, Neurovance will develop centanafadine SR for adolescent and pediatric ADHD.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Anthony McKinney
Chief Financial Officer
Gregg Beloff
Chief Medical Officer
Ross Reife
VP - Finance
Vincent Pappafotopoulos
VP - Operations
Catherine O'Brien
Browse more venture capital transactions:
Prev: 12/3/2016: Appier venture capital transaction
Next: 12/3/2016: Get Smart Content venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We document every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs